Issue on Jul-12 : Patent Expirations and Strategic Diversification The dominant theme across the biotechnology sector news is the critical challenge posed by patent expirations on blockbuster drugs, notably impacting revenue streams of major companies like Amgen and Merck. This issue is driving strategic diversification through acquisitions, pipeline expansion, and innovation in novel therapeutic areas…
Issue on Jul-11 : Pharmaceutical Industry Consolidation and Trade Policy Uncertainty The dominant theme across the biotech news is the significant consolidation activity within the pharmaceutical and biotechnology sectors, exemplified by Merck’s $10 billion acquisition of Verona Pharma to strengthen its respiratory portfolio amid looming patent expirations. Concurrently, the industry faces substantial uncertainty due to…
Issue on Jul-11 : Pharmaceutical Industry Consolidation and Trade Policy Uncertainty The dominant theme across the biotech news is the significant consolidation activity within the pharmaceutical and biotechnology sectors, exemplified by Merck’s $10 billion acquisition of Verona Pharma to strengthen its respiratory portfolio amid looming patent expirations. Concurrently, the industry faces substantial uncertainty due to…
“”” Biotopic Thursday: immunotherapy Nature Medicine 및 Nature Reviews Clinical Oncology 최신 연구 동향 최근 Nature Medicine과 Nature Reviews Clinical Oncology에서는 폐암(비소세포 및 소세포) 치료를 위한 차세대 면역치료법 개발에 관한 리뷰가 발표되었습니다. 여기에는 새로운 면역관문 조절제, 면역세포 연결자, 세포 치료법, 치료용 백신 등이 포함되며, 기존 면역관문억제제(ICI)에 대한 내성을 극복하는 기전도 다루고 있습니다. 또한, 소형 분자…
Issue on Jul-11 : Pharmaceutical Industry Consolidation and Trade Policy Uncertainty The dominant theme across the news is the significant consolidation activity within the biotechnology and pharmaceutical sectors, exemplified by Merck’s $10 billion acquisition of Verona Pharma to strengthen its respiratory portfolio amid looming patent expirations. Concurrently, the industry faces considerable uncertainty due to proposed…
